Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause
{{output}}
Menopausal vasomotor symptoms (VMS) represent a significant public health burden, necessitating safe and effective nonhormonal treatments. The recent US Food and Drug Administration approval of elinzanetant, a first-in-class dual neurokinin-1 (NK1) and neuroki... ...
